Laboratório de Cultura Celular, ICB, FURG, Rio Grande, RS, Brazil.
Programa de Pós-Graduação em Ciências Fisiológicas, ICB, FURG, Rio Grande, RS, Brazil.
Nutr Cancer. 2023;75(9):1687-1709. doi: 10.1080/01635581.2023.2241698. Epub 2023 Aug 8.
Melanoma is a skin cancer with a high mortality rate due to its invasive characteristics. Currently, immunotherapy and targeted therapy increase patient survival but are ineffective in the advanced stages of the tumor. Quercetin (Que) is a natural compound that has demonstrated chemopreventive effects against different types of tumors. This review provides evidence for the therapeutic potential of Que in melanoma and identifies its main targets. The Scopus, Web of Science, and PubMed databases were searched, and studies that used free or encapsulated Que in melanoma models were included, excluding associations, analogs, and extracts. As a result, 73 articles were retrieved and their data extracted. Que has multiple cellular targets in melanoma models, and the main regulated pathways are cell death, redox metabolism, metastasis, and melanization. Que was also able to regulate important targets of signaling pathways, such as PKC, RIG-I, STAT, and P53. In murine models, treatment with Que reduced tumor growth and weight, and decreased metastatic nodules and angiogenic vasculature. Several studies have incorporated Que into carriers, demonstrating improved efficacy and delivery to tumors. Thus, Que is a promising therapeutic agent for the treatment of melanoma; however, further studies are needed to evaluate its effectiveness in clinical trials.
黑色素瘤是一种皮肤癌,由于其侵袭性特征,死亡率很高。目前,免疫疗法和靶向疗法提高了患者的生存率,但对肿瘤晚期无效。槲皮素(Que)是一种天然化合物,已证明对不同类型的肿瘤具有化学预防作用。本综述提供了 Que 在黑色素瘤中的治疗潜力的证据,并确定了其主要靶点。检索了 Scopus、Web of Science 和 PubMed 数据库,并纳入了在黑色素瘤模型中使用游离或包封 Que 的研究,排除了关联物、类似物和提取物。结果检索到 73 篇文章,并提取了其数据。Que 在黑色素瘤模型中有多个细胞靶点,主要调节的途径是细胞死亡、氧化还原代谢、转移和黑色素化。Que 还能够调节信号通路的重要靶点,如 PKC、RIG-I、STAT 和 P53。在小鼠模型中,用 Que 治疗可减少肿瘤生长和重量,并减少转移结节和血管生成。一些研究已经将 Que 纳入载体中,证明了其在肿瘤中的疗效和递送得到了改善。因此,Que 是治疗黑色素瘤的一种有前途的治疗剂;然而,仍需要进一步的研究来评估其在临床试验中的有效性。